deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00433745

Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy

Wilm's Tumor 1 (WT1) Peptide Vaccination for Patients With High Risk Hematological Malignancies

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Acute Myeloid Leukemia (AML) Chronic Myeloid Leukemia (CML) Myelodysplastic Syndrome
Interventions WT1 Peptide Vaccine
Updated 12 times since 2017 Last updated: Jun 5, 2014 Started: Feb 28, 2007 Primary completion: Nov 30, 2009 Completion: Nov 30, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00433745, this PHASE2 trial focuses on Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML) and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 12 times since 2007, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshotCompleted~Aug 2017 – ~May 2018 · 9 months · monthly snapshotCompleted~May 2018 – ~Jun 2018 · 31 days · monthly snapshotCompleted~Jun 2018 – ~Nov 2020 · 29 months · monthly snapshotCompleted~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 7 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

  2. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE2

  3. Jun 2018 — Nov 2020 [monthly]

    Completed PHASE2

  4. May 2018 — Jun 2018 [monthly]

    Completed PHASE2

  5. Aug 2017 — May 2018 [monthly]

    Completed PHASE2

  6. Feb 2017 — Aug 2017 [monthly]

    Completed PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Heart, Lung, and Blood Institute (NHLBI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations